According to Zacks, “Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company’s portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California. “
Other equities research analysts have also recently issued reports about the stock. Canaccord Genuity set a $67.00 price objective on shares of Penumbra and gave the stock a buy rating in a research report on Wednesday, July 20th. BMO Capital Markets initiated coverage on shares of Penumbra in a research report on Monday, October 17th. They set an outperform rating and a $86.00 price objective for the company.
Shares of Penumbra (NYSE:PEN) traded up 1.43% during midday trading on Tuesday, reaching $64.05. 67,066 shares of the company’s stock traded hands. Penumbra has a 12 month low of $40.23 and a 12 month high of $79.49. The stock has a 50 day moving average of $70.67 and a 200-day moving average of $64.37. The stock has a market cap of $2.03 billion, a P/E ratio of 2562.00 and a beta of 0.31.
Penumbra (NYSE:PEN) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.04. Penumbra had a net margin of 0.61% and a return on equity of 0.61%. The company earned $67.20 million during the quarter, compared to analysts’ expectations of $63.25 million. During the same period in the prior year, the company posted $0.03 earnings per share. Penumbra’s revenue for the quarter was up 33.3% compared to the same quarter last year. On average, equities research analysts forecast that Penumbra will post ($0.10) EPS for the current fiscal year.
In other Penumbra news, EVP Robert D. Evans sold 6,300 shares of the firm’s stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $73.00, for a total value of $459,900.00. Following the completion of the sale, the executive vice president now directly owns 2,538 shares in the company, valued at $185,274. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Adam Elsesser sold 29,000 shares of the firm’s stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $72.95, for a total transaction of $2,115,550.00. Following the completion of the sale, the chief executive officer now owns 1,245,938 shares of the company’s stock, valued at $90,891,177.10. The disclosure for this sale can be found here. 22.00% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in Penumbra by 723.5% in the second quarter. BlackRock Inc. now owns 2,487 shares of the company’s stock worth $148,000 after buying an additional 2,185 shares during the last quarter. Quantbot Technologies LP bought a new stake in Penumbra during the second quarter worth approximately $151,000. BNP Paribas Arbitrage SA boosted its stake in Penumbra by 108.6% in the third quarter. BNP Paribas Arbitrage SA now owns 2,149 shares of the company’s stock worth $163,000 after buying an additional 1,119 shares during the last quarter. Legal & General Group Plc bought a new stake in Penumbra during the second quarter worth approximately $164,000. Finally, SG Americas Securities LLC bought a new stake in Penumbra during the third quarter worth approximately $202,000. Institutional investors and hedge funds own 51.91% of the company’s stock.
Penumbra, Inc (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.